Scientists compare rare tumors to improve care
NCT ID NCT07429851
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at medical records from 34 people with advanced, well-differentiated high-grade neuroendocrine tumors in the lung, thymus, or pancreas. The goal is to see if these tumors behave differently and how they are treated. By comparing outcomes, researchers hope to find better ways to manage these rare cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better understand how to diagnose and treat these rare tumors, leading to more tailored care.
- What could go wrong
- This is a small, observational study that only looks back at past data, so it cannot prove what treatments work best. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE CARCINOMA OF LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
European Institute of Oncology
RECRUITINGMilan, Italy, 20141, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.